ABC - Earnings call transcript Q2 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the ABC Earnings Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session. Instructions will be given at that time. reminder, is a recorded. As Instructions] today’s being call [Operator

your conference Cleary. Now the to host, I’ll turn over Jim ahead. Please go

Bennett Murphy

Thank financial we press a call, at Financial of will Collis, and also today’s measures, Cleary, Relations, On Results. press non-GAAP are and you today’s reconciliations Chairman, also slide measures thank am discussing in available Bennett this CFO. President discuss today’s accompany release, release morning, GAAP me to President, posted joining and to Vice I Fiscal investor.amerisourcebergen.com. Executive Good Investor We’ve website these Vice AmerisourceBergen our Quarter be for to on conference Jim website. today are presentation all Second CEO; on provided our they XXXX investor joining and Murphy, us President call you. for and are Steve

will conference income and an expectations on call, this our limited about EPS, During basis, not business we forward-looking financial income but taxes. to, non-GAAP make adjusted statements including and operating

Forward-looking on to expectations and current uncertainty based management’s and subject are change. are statements

risk update of and call you recent For permission express including cannot AmerisourceBergen rebroadcast company. most to obligation our SEC and release statements, key assumptions, filings, our we a XX-K. no without the assumes today’s any discussion forward-looking press to refer and be this of the

call in Steve. one many the participant will remarks We as the over ask management. possible per within after for that get by an your Steve? that, have hour. today’s ask limit questions to to I as You’ll to questions opportunity us turn participants you With to order to

Steve Collis

business and second as talk pleased unites well strong in positioned this AmerisourceBergen good chain the performance AmerisourceBergen’s today’s growth Bennett, I supply XXXX. how and you, long-term for good Thank solutions fiscal of the continued on citizen. our a healthcare how to highlight everyone will about stakeholders provider quarter and call, the On remains call. across am I to corporate morning the

fiscal quarter. XXXX increase quarter compared previous performance. fiscal second the second was Revenues billion solid of financial our per were diluted And the our EPS period. up $XX.X an to for First adjusted quarter, X% X% to year $X.XX

performance. which solid Services in and in our We dedication, are to mindset, the to Groups. of customer & want our strong quarter, are Health volumes, I I partners XX,XXX pleased growth them proud oriented our thank really driven distribution growth overall every by with double-digit our customers it performance be Animal and second and solution execution a Distribution the consider both was Commercialization Global Specialty associates for day. passion extremely and their more alongside I who first privilege and Pharmaceutical driving couldn’t focus work across

experience for teams to we the provide our of customers Our robust as enhance businesses value well and we continue in partners our that are portfolio executing across and the industry.

Services deepen patient specialty partners in ways Distribution continue and notably relationships unlock our physician services Pharmaceutical access team Our while new seek their systems customer to for enabling pharmaceuticals. and to value health to

Group continues Health execute, differentiated and of manufacturers for Global to services Animal pharmaceutical Commercialization proud Services and our we’re grow Finally, and how deliver veterinarians.

on Next for update an comprehensive financial PharMEDium. strategic and our review

the and the two to production We into quality best determined this consolidate the businesses and for open should on PharMEDium’s service smallest to that of the we facility As close automated way business the that more believe products. and safest part facilities least ensuring process, optimize of long-term, value safety business maximize and was the delivering the decision focus patient effectively. highest and that efficiently to more remaining customers PharMEDium’s remains appropriately while

and to independent into cGMP recall, consulting us this with previous difficult for determined quality quality that overall and evaluations unit’s unit. it president, levels help volumes our have and business the review in After we control may PharMEDium’s will In we be from taken to our next assurance years. procedures return few as engage cGMP firm business new the consulting of PharMEDium to you expert a addition, firm enhanced consideration,

and compounding we orders, In to review, consent addition commercial we have a distribution to continued at decree the would two internal the completion discussions our discussions continue with anticipate consent successful of on based to to allow Subject quarter. in facilities. third June regulators into the enter decree open to-date, expect party the we

will a in outlook. prior Jim Additionally, resumption that with specified must regarding on be more facility. these decree of to Based consent that comments operations details the his requirements Memphis we satisfied commercial financial provide update, expect at PharMEDium’s

this despite and growth to this evidenced strong execute and challenge results, and by performance. deliver continues quarter’s as However, AmerisourceBergen

Our driven centric remains a clearly differentiated defined strong XXXX strategy as in beyond. gains to utilization long-term differentiated and pharmaceutical have by from continued growth us well focus. across and our demographics strategy core continues in AmerisourceBergen to the investments market, positioned sustainable and innovation brand, the growth strategic specialty patient was and pharmaceutical delivering biosimilars. U.S. – of which At prescription fiscal our as benefit pharmaceutical

significant the an fact, to of breakthrough growth continue standards In the improve specialty number of medicines care. market and increasing current is experiencing

forefront of position specialty growing segments. rapidly places leadership undisputed at distribution Our this and in AmerisourceBergen services market the

decades specialty Services our portfolio built investments. in strategic in and extensive that we have organic Commercialization significant together separate represent report footprint they and and segments, of through we inorganic comprehensive While Distribution

increase. in with complex as Our Specialty and utilization efficiency is we why for medications U.S. the we practice create of partner The our life-altering well core our healthcare Services. enable reasons both the of as needed these to fiscal This preferred AmerisourceBergen part pre support to continued expertise continues provide value post channels choice. growing key patient oncology the products and continue capabilities solutions the to second Specialty and of distribution market and customers. and services customers, remains physician of combined Commercialization our double-digit physician in administered which we Distribution includes Distribution, quarter, us solutions empower growth a its

reach elevate and performance physician to non-oncology insights, example, relationship patients XX,XXX community products, experience. AmerisourceBergen’s over Medical accelerating practice and guide For sites, to their access extends needed the and technology Besse to

side, and span commercialization the pharmaceutical increase global Make the On it our of we the industry. for manufacturer services. essential continue the partner ourselves to depth

demand For world further example, with move such packaging deliver as strong the and services In and the years enhance clinical cell value, to we and like in and or across increased most those and World services. services issues of continues its of the demand technology which needed World ahead, complex in and innovative of forward growth products recent sustained for logistics exciting provide therapy. to gene their that in number for the empower manufacturers and and an flexibility specialty health partner logistics and dynamic opportunities should that arise increase increasing AmerisourceBergen services, high-quality their biosimilars commercialization and commercial customized innovative their in market pipeline NOVA customers, Cocoon, partners. advancements, efficiencies the applies and landscape. provide Courier, all and towards the Korea our for this which same experience innovation innovative trusted care masthead that distribution innovative support trial specialty

stakeholders data our offerings to entire as value-creation needs of meet solutions and upon trusted position in depend Our enable AmerisourceBergen’s a our our chain. to opportunities throughout all and the Likewise, health continues and focus differentiate stakeholders customers them our care our ongoing the services evolving and driving in company investments efficiency for supply data our at industry new to on and our deliver partners, state-of-the-art connectivity solidify ability scale. further help care distinguishes that business improve

transparent and our As reliable, an industry, consistently and stakeholders. AmerisourceBergen value that nationwide supply secure [indiscernible] accessible deliver data that chain analytics produces for

For service their and services example, enables them inventory which their daily trust and AmerisourceBergen, manufacturers by levels. data value proactively and to manage daily generated

a operational help data chain, and Network On pharmacies responsibility trusted mind, prices pharmacies the can patients our role supply set U.S. if to pharmacy as oriented system this facilitation a provider the the discounted supply at end of in improve pharmaceutical source we empowers role that access analytics the great our a solutions With tools solutions health enhance approach care. point-of-sale. other continue where and pride one of our play maximize with to in profitability, in take Provider the believe to and Elevate we chain. shifts patients’ in there’s our as needed unique effectiveness care We solutions X,XXX that the

we trusted fundamental AmerisourceBergen its Distribution would relationships, peers tools be best believe transition. and our and the Given Pharmaceutical to support positioned

proven of operationalize AmerisourceBergen’s a their industry distributors’ a and of united pursuing AmerisourceBergen facilitator experience building systems unique to existing responsibility and create potential capabilities manufacturer are trust handle system existing this pharmacy in and and approach fairness model. point-of-sale healthier charge-back Our fair, relationships pharmaceutical and ready efficient the today the transparent. support distributor administration that purpose to pharmacy partners, with discounts role distributors our solutions built to will complex With in and to opportunity the contract on is with provide futures. reform charge-back in customers – blocks further embody a position This being managing necessary play maintaining alignment,

force the In fact, driving behind everything our purpose do. is we

value recognizes company, the citizenship long-term a creation. As as of AmerisourceBergen importance strong cornerstone to a shareholder corporate

and most excited continued date. for follows sustainability which We comprehensive the Report, and to this is detailed accepted progress report especially Corporate externally our development Citizenship by reporting within standards are year’s

Here are a few highlights.

help centers and energy solar and weight operations. packaging introduced invested the energy reduce in efforts our have solutions pilot two several our at in to innovation our we of that sustainability First, improve located distribution usage projects

Respect project hurricanes enhance Assistance another, by help Connect With we where colleagues our support campaign launched wildfires through to and respect inclusion and supported our the addition Associate one impacted our Fund. and In associates

in the human prescription charitable-giving invest and AmerisourceBergen for organization populations help safety. not-for-profit, care an ensure animal that Foundation, and to increase causes access Finally, drug health continues independent, health-related

a by from the manages chain AmerisourceBergen in seriously providers. role the opioid secure and to safe including highest integrity As distribution, for substances and advocating licensed community operational manufacturers transportation to the combat pharmaceutical of ensuring regulatory medication, outreach. We controlled standard and take distributor maintaining supply and abuse work our of products,

AmerisourceBergen this, all communities Foundation XX,XXX create boost difference and improve In our reporting across country misuse. to making all. Directors are creating suspicious closing, orders and controlled our the to further a to substance continue of Together, the is continue committed our reach All the efforts, healthier shareholder our the associates, sustainable in to providing positioned chain AmerisourceBergen will value of and our across to opioid of communities for holding communities in addition supply a well the future partners and DEA delivering and epidemic collectively orders. long-term AmerisourceBergen combat and to to Board growth. and resources working to

complacent. our for our value and meet to ultimately transform be ultimately evolve of to patients patients. proud and our the drive stakeholders, ability our partners, – of business, We We’re and execute serve needs won’t even

investment and people, solutions, infrastructure an business. problems access or customers that committed our opportunities and our making solutions in in on We’re that thought the is to additional create and being have drives the their efficiency. focusing AmerisourceBergen enabled leader

the and create healthier appreciate have our always, that differentiated we long will confidence stakeholders. utmost AmerisourceBergen. responsibility are our united to We for created strategy in ever, than More venue our term sustained we future as

Now, of turn to our will revision EPS a results quarterly financial Jim to Jim? discussion over call in-depth the I guidance. upward more for fiscal our XXXX and

Jim Cleary

good Steve, Thanks, unless only against remarks and made noted. March financial year focus our everyone. non-GAAP today and rates adjusted quarter, on My the comparisons results, prior otherwise morning are growth will

For release. please earnings our results, a GAAP our refer of to discussion

AmerisourceBergen proud halfway of of year, have extremely deliver are reached strong to we results. the As throughout our point the execution fiscal we

Our especially from this PharMEDium. that notable continued has given headwind a year-over-year performance still is quarter strong impressive

ahead, expect to quarter. last notable any headwind the Looking in June beginning we to

continued QA/QC the new of have was firm. in morning, take accordance that to enhanced GAAP of to PharMEDium our PharMEDium’s conclusion asset This we implementation now charge with business, discuss volumes lower will want first closure for this that I on the of a moment of I the our expect discuss evaluations President PharMEDium. the current analysis Before Based reached we Memphis. to have impairment the taken in due the procedures results consulting and CGMP

our end. updated outlook comprehensive, As and we long-term the part at financial of strategic quarter review,

cashflows as amount to facilities the performed of is make sterile this determine few future tests reopen on for given lower but overall used other of preparations, finalized, flows well subsequently a the value as million. the a expects compounded is We fair with consent expectations. the should continue using to discounted and the cash see production After indicates carrying pace demand remediation a We operation, over the we and asset a PharMEDium undiscounted impairment estimated to Memphis have assets We to decree the probability production variety that maintain further to clarity requirements that determination. that years, determined $XXX ramp scenarios value. waiting limitations the a have next there estimated

reminder, operating XXXX. a $XX is As of represents for fiscal about this PharMEDium income in headwind a And loss about be fiscal to XXXX. expected of X% million an adjusted

XXXX, For profit PharMEDium only a comparison fiscal small a in fiscal down had XXXX. income in from purposes, income significant profit operating operating

discuss continued main AmerisourceBergen. now quarter will this Turning to areas two results I morning. second the our in strong commentary by execution and provide

First, I’ll adjusted segment performance. detail and our consolidated quarterly

Second, I’ll to revision EPS XXXX cover the guidance. fiscal upward our

in now to quarter and $X.XX, lower later primarily with has positives, the an a expense general I expected lower and quarter and X%, that administrative Moving in of be quarter net due the just finished interest year. results. of to share count. higher expense, to our We will were realized operating diluted second second been items there the increase that note EPS some adjusted income,

was in profit revenue by X% $XX million. up consolidated growth Services to Distribution increased to X.X% operating the X%, revenue primarily million billion. or $XX.X $XXX driven Consolidated expenses increased segment. Pharmaceutical Our strong billion Gross $X.X

for and ups costs, would which there These expenses a Normalizing our of sold were the would while impact quarter has some true both costs operating recognizing our last have the income X.X%, As expenses. remediation fiscal those profit the X.X%. in accounting on comparison. related year, impacted increased increased operating items have second and for of this out reminder, net PharMEDium’s no to adjustments gross quarter XXXX, good operating

this have solid to we managing we effectively operating expenses focus continue expenses expense operating quarter, business. throughout overall to on relates the as it management, As be

million, in management is positive and quarter. impressive secure while efficient important flat. especially items general operating Additionally, were the our that X% that represent essentially the management, to continuing access expense strong patient on and I administrative and the care. EPS $X.XX income $XXX earlier execute healthcare up service to expense safe, Consolidated with customer operating so teams our referred Expense to to of it’s and able in delivering roughly ensure was industry margin,

strong businesses had As related quarter operating headwinds to we or previously the was Brazil, to to PharMEDium. this normalize in quarter quarter. which That by the results offset the we highlighted, March expect last income from headwind consolidated we in mark significant third expect our

operating income. growth the discussed lower the would consolidated have If to Brazil, our you an Net earlier. operating expense were expenses held PharMEDium increase both been million in consolidated I quarter increase interest to X% and exclude still by income in to as than due interest expected $X $XX million,

better expected Given lower strong expense interest to be year-to-date the originally now cash flow and anticipated. interest we net our than income, than expect

items. XX.X% quarter, now year due our income slightly to income Moving primarily from up relatively tax taxes, rate was the prior small discrete to some adjusted

tax a rate As the year tax reminder, order benefit did the prior reflect from reform.

on $XXX our $XXX last we share repurchased count shares, the approximately repurchase million. have million share decreased repurchases million in authorization. Year-to-date, total now quarter shares roughly diluted and remaining have quarters purchased in we million of million Our now X% over November bringing the share shares, $XXX the four $XXX of to our XXX XXXX to

flow between balance, year cash to year-to-date we billion. of for $XXX cash adjusted us $X.X on free track adjusted flow cash had with putting free Regarding cash $X.X full flow of our right million the guidance billion free and

earlier $X.X We This than of was with results. flow which billion the timing U.S. of the our expected. cash in and million cash. completes Although consolidated of the held ended $XXX denominated was quarter review free majority offshore with the the cash year in

of of Segment and continued billion our Pharmaceutical to was largest income I’ll Services, to revenue customers, in growth about $XXX cover Now from continues growth. with specialty This up market some strong benefit X%. Beginning X% its segment growth overall Distribution distribution segment $XX results. segment increased operating million.

have income quarter March but As to Normalizing the segment both by discussed favorability impacts, of earlier, still headwind PharMEDium, the operating related was these would a from Brazil. had X%. for increased offset

distribution Our continue expenses. volumes our growing while customers, with effectively businesses operating extremely execute core well pharmaceutical managing to

million to up In all supply was the in winter of it growth customers with quarter, in upstream half Our deliver limited network. and specialty groups other continued logistics expected, side rate Animal Health, MWI. Canadian income billion, Consulting’s and efficiencies of teams and standpoint, to year. working anticipate while businesses solid solutions high focus we the growth continues primarily due to innovative momentum up and operations, as strong conditions revenue demand MWI’s product as strong at The the Consulting, we to the operate X%. deepen had and improving income relationships MWI the AmerisourceBergen efficient back group up at had cost the specialty has severe Courier strong $X.X of World X%, growth solid growth services turn market. touch Courier volume X% revenue by partners and are on World global commercialization From Innomar, efficiency the continued impacting World had Courier. to most trends. drive revenue as chain manufacturers, production operating its strong. total across income as an was Courier, growth global deliver operating includes their and the World group diligently growth that this be I’ll Consulting’s the to for services continues on increasing solutions, business. is increasing working $XXX operations animal and weight with operating Canadian the and access Canadian segment, or both now including existing while outstanding distribution to which downstream to

continues While Lash. a for transition XXXX to be fiscal year

winning of The for differentiator be as continues renewed platform to business business, for manufacturer we having long-term. have relationships and to anchor adding business review the the a offering This programs. fusion We’re long-term the Lash’s success completes of had service and addition and segment positions results. key or the well excited our in for new outlook notable the

our I’ll guidance. turn XXXX to now fiscal So

headwind As $X.XX, at diluted for only we $X.XX as our said raising our of are $X.XX, a expectation we fiscal to guidance change is this outstanding high businesses level, a are $X.XX morning up year. in we PharMEDium. from updating to our execute for this a item weighted XXXX the despite minor shares adjusted morning’s to continue other press guidance range EPS to release, The to from the

this year, for Given far our for our year. down expectation approximately million the so are to shares million approximately the shares, from XXX previous shares buyback outstanding we weighted expectation lowering of XXX

Lastly, we our note are speaking, assumptions pricing our relatively relatively in but our of year, are pharmaceutical and for for expectations after the fiscal I’ll in pricing year. not making with working to half year. changes the any Broadly it’s first brand the line year, both the around that original fiscal trending early generic full still

range factors operating factors us how are capture. guidance H. performance, and Turning move D. these less Smith likely today, that bottom Based mix range. the and we our are overall, from expense we management, synergy back results range and our PharMEDium, our to include, on evaluating unit brand business be pricing at within generic of to

continued along and to decades strong the we developing a built customer robust provide updated referenced expected note strong key the ensure our having earlier AmerisourceBergen in guidance. of the expected initially all partners and for I will capabilities, attracting evolving of are rest as and rest internally benefit In of deliver year, to results. items and year relationships we to portfolio execution and align we do businesses you throughout actually not full of enterprise quarterly mind, the the closing, with externally for today, extremely year third proud investing your discipline quarterly fostering cadence financial interest Regarding spent talent become has while are AmerisourceBergen to for expense that offering the quarter, certain for that were Thank the unparalleled models your Keep EPS we’re in value guidance, our adjusted and quarter. maintaining adjust the benefited efficiency. you AmerisourceBergen. the March our but to

to our Bennett here’s start Q&A. Now

Bennett Murphy

we’re ready first question. for our Operator,

Operator

question first will from from Santangelo Thank come Securities. you. [Operator Instructions] ahead. line Guggenheim Please Glen go of Our

Glen Santangelo

impacting offsetting core taking for was sort to I Thanks margins than wanting we Steve, came mean, assess way. what’s distribution margin question. the is get what given for Brazilian And Brazil. and the color channel you’ve going maybe us if be Yes. there, about we happened the the Jim, pharmacy and of business. of better follow-up gross follow-up and just us piece mean my unpack sustainability how independent just the The may can reimbursement pressures us biggest from some And my that were the could gross PharMEDium you at the I about economics so what within of looking and pharmacies could intermediate retail question over out trend. in what longer little that investors in then getting better for. But on wondering wholesaler that term. the help a we’re bit I’ll help on the

any So two helpful. thoughts would those on be issues

Jim Cleary

I’ll Yes. answer is Jim, take and questions. Glen, This And then question. Steve second will thanks question. first the the the for

efficiency benefited call out tailwind margins, particular distribution adjust and regarding a the had X%. distribution of revenues we that about And things. couple take and feel quarter, focus the And into on security. business, PharMEDium our in big-picture particular good out added many wraparound in there provide, is other margin are provide, that growth. that was services during distribution, growth will though, a X% margin. financing margin One during We income thing really had is on justified as a of out are prepared to the And There quarter physicians. I said and clearly that’s that there logistics out I across just fair we units. asked step X%. still were first performance call proposition you really operating good particular I provide, income in we operating very this quarter. out specialty that as And getting in kind operating from nice noted management. that and and from call operating as as So expense our and me the performance standpoint kind about benefits and and are $X.XX we business during in margin. administrative received from the the we up quarter quarter is of I’ll say I’ll you we Brazil, expense up call including played during and services quarter quarter quarter, let up year. had But our was in was operating were we I’d and of receive we the and expected And by that over now the balance I’ll that margins about headwind back we thing us confident access which And the of high remarks, value a general one there the our in services talk to the and out my And performance the the

don’t is quarters tough down we don’t and comparisons headwinds the the we operating with quarters. with our in that – then pleased as income And operating notable forward PharMEDium really past notable of pleased lapped front us benefit one headwinds really that going that we’re expect have But them and going in really the so thing our and will us on that future that help performance the forward quarter. did overall, our in margin. we have growth comparisons And course,

Steve Collis

your strategy. it – informs Yes, thanks. Glen, a lot – pressure, depends by a lot second really really on customers the contracting our reimbursement question, around

rates our know really we networks, we on do discussions that example, we of of if a the Elevate important that. So all got you is contract with account when narrow And we of a independent in have that work, into that of it’s we behalf take the lot manageability you’re have contract particularly, for base There lot talk. Elevate. for

I fairly think And referencing market this seeing independents’ can in remains consistent. we’re share you’re independents environment? survive

because role service communities accessible. I petitioner, as they the local provide, in, that differentiated a think the very their of health care they’re

But of helpful the are think, so survivability been think work overall then to key I industry independent service and there’s services, I has lot ourselves, differentiate to groups. And we including a a sourcing professional continuity Thank think fine we we and other very you. there you and I critical Elevate their patients that And that have within the very of, important survival. partners of differentiates that, subset. them, Good them. pharmacists. hard. further Pharmacy think they like they Neighbor in And are And that member fond analytics, growth the services, think they of being our offer very technology, a services particular – very do

Next question.

Operator

Thank you.

next then Jones ahead. Our will go Sachs. of Goldman the Please from from line Robert question come

Robert Jones

lower to that than highlighted, the questions. question if have the you it for Thanks this $X.XX I implied that on back account the is results original up expectations what for based last seems on just I quarter to like would of before first guys seems it guess to be you, in better, much been the half pick your flat today. the for Jim. quarter anticipating G&A for Even obviously like still positive you came

you’ve at of flow wholesalers follow-up a could times funds mentioned play the the curious and Steve, now share. just I’m there potential a if point-of-sale dynamics So there’s discount be being of ABC any would few And my about then a world. to that other in facilitator you

So just stream you of hearing significant what now be wanted a from to that a group? the ABC quarter how later, get Thanks. sense a And and revenue of this D.C.? could we’re for out and you, are profit

Jim Cleary

then will answer second question And Thanks. first again question. the the and answer I will Okay. Steve

move of at Smith performance, D. the capture results the generic that the and guidance and are to brand of look that as but we range, move consent said PharMEDium, year, remarks, factors I’ll less the to consider, less extent, that seeing we evaluating that when at of of the some then still But and indicated from course, generic us other us $X.XX of unit relatively just current bit I think year, that we year, over was expense the out our members little And I prepared negotiation to it’s Memphis. balance I $X.XX. our was of not results PharMEDium what that we H. Regarding ones range all factors we’ve operating how course, a to we balance pricing, guidance increased with would those the for based are low the end one the today, our are the the as decree. is business I range, from beginning the it’s the likely did what our range. on under the downside important year, during PharMEDium the scenario of expectation. end synergy we’re management, mean, the our at think are important and the range thing given of call course, pricing, reopening control, of early the brand $X.XX. that to probably within low And And at And is and of our bottom in of the to the be

AmerisourceBergen overcome is increase strong And numerous so able fiscal been pretty early But range it guidance execution the again, I’ll that across comment still and businesses. our due year. to we’ve to that in

Steve Collis

think that talking very And that would for rather the one to I about approved, say, start not as that for much like lot the that. the of been And a question. generics be portfolio on play not of – much I’d we’ve that we’re work had this thanks sure hard – think balancing an products profitable. Bob, growing, obviously state out. I I about that we years. And where our make we just Yes. everything talked thing frank a And be And are very we’ve of effort headwind our to and make was But we’d that deflation, portfolio some I that to seen not sure generics part a a all as headwind. in robust you’ve that past, the with entirely. to

There talk resources, could our to gets of the put team. digital you company, adjudication, not still to great the the release way time that a the inner thinking and people here be think you on brainstorm finest tremendous a think I amongst Just is look really operations not – the business to was rebated. I that do are about said the about there. give cooperation the get proud our people, at solution – that stakeholders. some long just information and needs the the in that we picture. the I’m workings I question heavily core out all Having a mean it’s about proactive before done will into products and people between a glimpse think done amongst it that out distributors of the clear that, the to about sometimes between elevate industry resources be putting work done of future, there, question. information problems we’ve work really all we

and fairly of which have prescribed category insurance they how with and how a utilize patients get them get characterizations is products, around and are about negotiating talking other and We’re they large dispensed and specific PBMs how how parties. manufacturers

positive So I we But role. think that’s important. our about are

that data analogous payers and we state claims. to quite a intellectually other feed provide. confident been it’s have take more because some services we we’ve confident, can from I that’s this service But complex to to perform we think

So we to that the right that. do work. are and to the stand we alignment ready party need do wholesalers We help that need

We party. a because we institutional are that the we frequently. faith very setting an confidence honest, this have in can do that and we And strong neutral do

for leverage. time it’s saying big a that that the payers. relationships terms long not stronger companies of we a over to provide us. stretch have for payer/patient relationship a it’s will think strong services we that AmerisourceBergen So I like these a And inevitable And in been time, that we that have of can I’ve

the that’s forward that of playing to we evolution and look role. maybe market, the of So part

Robert Jones

Steve. Thanks,

Operator

you. Thank

Evercore come next line from Please question Muken ISI. then of Ross from the Our will ahead. go

Ross Muken

morning, Good guys.

what given of – things have other two just in there’s maybe things, WBAD sort So less of is some terms and maybe your of environment. go terms some deflation But they procurement independent NCPA of from the is against theme, the for a in sticking good with procurement anecdotally and generic obviously, about year sourcing fees had. those than sort less issues base numbers just partner and customers, And other savings of what each better seeing this after kind need. heard the the obviously DIR the are and on slightly and they you of Obviously, you of a tougher we’ve generic also more generic seeking is guys. and talked what environment independents independent

you them, in market offering push so sort of incremental kind And did more of the of of kind can guise of pull need generic maybe past you and this of important what you in what they kind base today? customer do they keeping is services, the maybe than versus guess the provide healthy, I balance to that how

Steve Collis

it’s Yes, good a question.

I Boots everyone, is now time. that that has been Walgreens years to WBAD at joined and old. six alliance And Alliance been it’s already in created the that successful. think So we just mean XXXX, we between very remind

narrows for well with think it really historically, if And how look wholesalers that that sourced can. into the I’ve help theme fact, chains between overall In you how about gap been have independents. back, the generics I about, how very versus independents tremendously survival of talked important does

look a wanted very our we to And you talked and carefully. rates that. our what are. these at between we’ve compliance there’s And about generic what if So juxtaposition, profitability is take, statistics

our we and that obsessed We compliance of profitability with look giving as our independents are fair our a important feel we’re this all them business. rates maintaining segment in the deal

proposition been stance. us. that’s something So the to policy It’s new always it’s aware to pressures and in to that not of customers. of. provide we’re health It’s and that the us. Neighbor that nothing it’s – other we Pharmacy our new – we to are something we are is value care very confident are reimbursement all Good And But aware pressure not

these our fees, have went We key Vegas really really help. better to much our now when could be three and exposure surprise. much were managing to discussions engaging referenced in intensity DIR I accordingly. I we help ago trade in that. position what years pharmacies about show, think have for to more been those you base so try proactive I with a changes. fees can suppliers about understand to the in manage plan discussions of The a was through those that well been more About we DIR that those, our as and as customers And to and in are And – independent people the at really the are surprised

things that. necessarily, So opinion, we’ve help through But that not base been some our we feel in those manage have fair. been able my to of

So question. next thank you,

Operator

you. Thank

Steven go Barclays. from come of will next from Valiquette Please the Our ahead. line

Steven Valiquette

guys. morning, Good thanks. Great,

price not generic current really data to a list environment, generic be that on lot stabilizing, a prices distributors price, from four pricing. right there a about down now. generics, materially, anymore really up here going around topical just that in little earnings of it’s So ago a increases. years a not the Obviously, very question Thinking were up pretty going generics of generics seems were more based going at. of trends lot looking but or the lot really least drug captured In five in back bit we’re when lot a upside at price the of of

profits potential are the So level, current to important capture for able that Thanks. distributors in maybe just to about you high at curious the that thinking environment? is a when incremental how thinking discuss

Jim Cleary

Yes.

is range seeing regarding what deflation in the So generally our we’re expectations. that the generics, original is of

look long at the call and basis. a the we of we the is as at it percentage see range, original said particular year, expectations. we overall, beginning quarterly generally to in that as a of it out in when as range on we our stabilizes that So won’t And

hopeful from are that on stabilization. the portfolio manufacturers further We optimization to commentary leads

market there. levels digits a relatively – things seeing small. it’s market that’s in seeing of one kind been terms are that just returns in of period We’re on optimistic over time deflation. mid-single that the we But we’ve the historic supply constraints, of impacts of then to of the And some and volume

Steven Valiquette

I day, trend? think, really, at the buy-side day. right sell-side pricing a of the I the guess end pricing are between critical you at generic the consistent trend the relationship generic of the seeing end now That’s what’s versus

Jim Cleary

Yes.

And as constant. have terms tracking that. we’ve We of spread relatively that been that seen spread, in

Steven Valiquette

perfect. Okay,

Okay, thanks.

Operator

Thank you.

of question comes line JPMorgan. next go Lisa Our from from ahead. the Gill Please

Lisa Gill

just the talk if you I’m could impact wondering Good a around about Medicare little maybe Part Steve, B. changes potential morning. on

your growth see risk do about business B do reimbursement But see on your to see around you specialty we specialty you start the talked and You Or side? changes to opportunities incremental any Part if business? there.

Steve Collis

reporting, if A well And our at in franchise our companies, growth acquirers. there at colleagues is moment around of our the product doing look are business this within had pharma are oncology. innovation so some the customers, larger seeing colleagues – incredible really And the the a specialty fact, in we’ve the on segment. side. much wins is have you lot and, from The key you’re that manufacturer manufacturer always it customer that which we about, of the consolidators, talked some reporting, that

of good And within right bit fair market far as macro really the think up data. gauge customer of actual of – And that So Part think as invariably to growth access some that now. hard distribution important our we gone share distribution business. I a referenced have specialty could because Jim exactly data there – ahead it’s reimbursement don’t our share is we’re to trends our the seeing that to the AmerisourceBergen market our pertinent But because goes, base. we think B

I’ve more beneficial, I And are we But as is there that are some to commercial We changes, skepticism think be hope overly new rely oncologists could there’s talked concerned really a there Part their these base. be really, sustainability fees. about could far of the on lot that of B. about the as fees. those that some nothing around maybe

important and hopefully play positive a [indiscernible] particularly the that is commercial what that with patients. is Medicare think role I community oncologists understand

trend. that urology, we cetera medical that the trend Another is Bs. why And like that’s access areas the part ophthalmology, And Bs basic is our Part business. we’ve of got in Part we’re important et seeing of drive highlighted more not strength

question hopefully, that and… your answers So

Lisa Gill

of the the $XXX million playing that rest this helpful. as left we That’s about that’s out down only checkout think million we when by the How follow-up, year? just throughout repurchase, And Jim, a you’ve in then brought roughly the shares. do think X share about

Jim Cleary

Yes.

don’t a the capital guidance. so include in And unidentified allocation as reminder, we

past As as we But capital part look said we said repurchasing of the in million quarters. done I at we’ll opportunistic capital repurchases we’ve during guidance. as don’t the allocation the to worth continue our before, share allocation. of four share $XXX call, unidentified And include over

Lisa Gill

you. thank Great,

Operator

the question And from come will Please from our go Caliendo ahead. line UBS. of next Kevin

Kevin Caliendo

my I call. Thanks animal the for taking about talk change want little and a business. it up health bit to

negative meaning into about little in a on, these side. can MWI MWI? quarter, of on purchases. of caused mentioned timing a any the the of morning a distributor bit distribution you going there talk U.S. for weather impact dynamics their miss be next You Can production the bit be makeup? little out a this livestock the what’s had the Zoetis on could or there called partially pushed the a And on Is production business side delays of by

Jim Cleary

Yes. during And prepared the said I as quarter. MWI X% my during remarks, grew

severe said winter In weather. fact, limited because I the that, of was that

I it during impact as say, would in production long-term, But did an business. some from It And [indiscernible] very of answer healthy quarter. on an have the next animal second fiscal very during I’d of to impacts business. that follow to the have really overall, the And time time. than comment that that sometimes question, flow overall the the weather Midwest that animal animal companion the you have your those weather then and to so grew is animal some that as business And make faster it or positive, follow of over some happens to we of lost the of will production just kind business. into health quarter, view long-term a quarter.

Kevin Caliendo

Schein But the Covetrus you businesses seen the any On the yet in the of merger, Choice and a merger impact from has it’s only – Vets First been know side, yet? quarter. companion I marketplace have the

Jim Cleary

are Schein good Yes. and Covetrus competitors.

And areas they and one just to continues we’ll on We focus good them. that are of in have competitors market of strength. our

strong corporate particularly accounts. We’re in

strong in efficiency in operating We’re particularly business. our that

We in the have value-added market, production a animal force. services and both animal in sales market and good the companion really strong technologies

will to to good strengths the So sure been, on and we’ll building focus competitor. Covetrus I’m that a business. be, in our continue continue have strong But they as

Kevin Caliendo

own your – Vets there to Choice plans Is the similar First Vetsource any just to grow try platform, platform? to out

Jim Cleary

Yes.

other shareholder interest have have are with that for them. technologies of we’ve Vetsource. happy like internally. our [indiscernible] very in then business value-added And and we We kind we with been instance, a of that And partnering

Bennett Murphy

please. question, next Operator,

Operator

Thank you.

question next the come go Cowen. Our Please line will of ahead. from Charlie from Rhyee

Unidentified Analyst

actually. Charles for on James it’s Hi,

give grow And level some So If growth? expect operating World to seems profit previously of like well. you continuing in correctly, be of line perform at Courier to I recall was that to growth Can noted expectation? there that XX% in you that what’s it or over is Has on excess color XXXX. term that driving XXXX? growth beyond fiscal in us the sustainable with longer year-to-date been fiscal

Steve Collis

high-growth three a provide don’t within growth outstanding services their specific very very year, did were business an didn’t and But to pleased they’ve Courier. we with put manufacturer years, important continue very business two more the internal hit milestones, they when has – that And to back-to-back importantly XXXX their strong partners. a So brand and for or guidance with in give we we have we no, World James, year [indiscernible] give

business the a for add ABC international that be of business. the has we run And So It’s an couldn’t management the there. happier value been success high We’ve countries. operate And that the done you in back to It’s investments. that’s with XX strong out. complex with confidence business business for terms internal cross manage us. We’ve and you inform the we really have over a in strong of a lot was a made financials, been how there, management, them added controls, contracts strengthening data. expanded time, business. and good lot internal a We think a the the has just in really always and helped helping if it services look long us

case acquisition. study for great a ABC So I what a is think within successful it’s

Unidentified Analyst

tracking with towards implementation? great. the growth Lash can an provide on fiscal maybe, Fusion return to Lash XXXX? particularly us Okay, in is you How And update

Jim Cleary

Yes.

in making. and progress But Fusion signing and and business still new feel transition Lash. really programs that patients. really year a development for we’re really for new Lash pleased for for the strongly the From terms wins and and with have So and long benefits they’re that about a Lash is business well the doing financial it’s standpoint, adding the customers. will And for extensions existing it we current with manufacturers and term the of

Bennett Murphy

please. Operator, next question,

Operator

Thank you.

come next Stanley. Please from go Morgan line Our of question Ricky from the ahead. will Goldwasser

Ricky Goldwasser

Good Yes, morning. hi.

highlighted about about lower when a two-part both operating we think the a model talk we this $X.XX to some But should I of from expenses, that as going headwind forward benefit And of them So item? largest kind onetime obviously, benefit. meaningful question. sourcing more I just is a then your Jim, WBAD sustainable wanted we generic or the a sourcing from quarter question. Jim, can the the like benefit partner in lower has mean for and run Steve, revisit first, for customer just

from So Should seeing what stable. we buy-side interpret responded I you on better are you’re your you are versus sell before being that that you the the seeing end? as getting sell-side? – it? pricing How mitigating the you’re spread know actually

Jim Cleary

that $X.XX the throughout benefits up the Yes. take of balance to ended in third that happen in And part really of the expected The that us quarter during quarter. it’s the we timing. first particularly second question. benefiting fiscal is the G&A quarter, things year, of the I’ll

Steve Collis

the works an and really like Walgreens, partners, and we strengthen also relationship Alliance of think Express I because our but between especially the sources we Boots also institutional AmerisourceBergen data and has PharMerica. WBAD, – the been On pharmacy strength very Scripts a have that Yes. of key further partner have the

like painfully of growth inflation generic really When are feel brand the and we we well and specialty. it’s of aware positioned. So we – deflation

$XXX definitely contribution our in when thought continue we’ll planned So we planning. it. is about at something a revenues And of from you year think profits, billion contemplation the XXXX look to and the the about lower in WBAD fiscal

powerful, very we and original the component very sourcing be we very good copyright. partners have the in models sort of have important. will – successful, have. informed is to the that the So of stakeholders the other stakeholders stakeholders are We think original course, But that

the I actually getting out. hope So time I’m is that –

that turn So to Bennett. I’ll

Bennett Murphy

have we question last the closing that’s call remarks. time I’ll for turn the back over Jim And But for. to some

Jim Cleary

to and for a having Steve, to year of off-script milestone AmerisourceBergen recognize then Yes. associate. just congratulations, leadership go just AmerisourceBergen to an Steve your moment celebrated And years your going over a turn take it closing I’ll remarks. service and bit and I’m stakeholders. XX for I’ll his and all for just for Steve XXth But here thanks as

Steve Collis

honestly, Thank as ready as I yet. of you, Jim. senior people a someday, sit quarter. but I hope that for fabulous I’m we here will think me had today, a that spokesperson, not But

also grow the we had. do And I in what if than think in requirements confident pharmaceutical to the critical magnitude. space, in But services and proud that management scale, to I continue our but that’s I’m about provide proposition. patient in AmerisourceBergen the We’re of really our to access does, they and in to ever the results and health more downstream. upstream outcomes to customers, And And they’re facilitate of both key that we value feel care. quality, whether are

ever that XX Jim, financial in differentiated deliver strong care acquired future, health built, the U.S. we’ve you relationships value. company feel our XXXX, system if very I and businesses of we’ve built, cultural the can people, successfully key So aspects flexibility you portfolio, the had shareholder our in have, financial we we’ve and that that confident since years, at that the the look just we mentioned and merger of most the the but services really long-term solutions complexity probably flexibility the the navigate we’ve

appreciate from I of questions interest community. you you. quality thought sell-side today our So I for thank was Thank in AmerisourceBergen excellent today. listening. the the your

Operator

and today. you. for for our conference Ladies gentlemen, and TeleConference. conclude Thank that using Thank your participation, you for will AT&T Executive

now disconnect. may You

Cencora (COR) 2 May 192019 Q2 Earnings call transcript